Masaaki Iwatsuki

Prof. Dr. Masaaki Iwatsuki

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TITakatsugu Ishimoto
Takatsugu Ishimoto
KMKeisuke Miyake
Keisuke Miyake
TNTannistha Nandi
Tannistha Nandi
MYMasakazu Yashiro
Masakazu Yashiro
NONobuyuki Onishi
Nobuyuki Onishi
PTPatrick Tan
Patrick Tan

1 February 2021 in Cell Reports
Verified
Journal Article
Open access
TYTadahito Yasuda
Tadahito Yasuda
MKMayu Koiwa
Mayu Koiwa
AYAtsuko Yonemura
Atsuko Yonemura
KMKeisuke Miyake
Keisuke Miyake
RKRyusho Kariya
Ryusho Kariya
TITakatsugu Ishimoto
Takatsugu Ishimoto
In the tumor microenvironment, senescent non-malignant cells, including cancer-associated fibroblasts (CAFs), exhibit a secretory profile under stress conditions; this senescence-associated secretory phenotype (SASP) leads to cancer progression and chemoresistance. However, the role of senescent CAFs in metastatic lesions and the molecular mechanism of inflammation-related SASP induction are not well understood. We show that pro-inflammatory cytokine-driven EZH2 downregulation maintains the SASP by demethylating H3K27me3 marks in CAFs and enhances peritoneal tumor formation of gastric cancer (GC) through JAK/STAT3 signaling in a mouse model. A JAK/STAT3 inhibitor blocks the increase in GC cell viability induced by senescent CAFs and peritoneal tumor formation. Single-cell mass cytometry revealed that fibroblasts exist in the ascites of GC patients with peritoneal dissemination, and the fibroblast population shows p16 expression and SASP factors at high levels. These findings provide insights into the inflammation-related SASP maintenance by histone modification and the role of senescent CAFs in GC peritoneal dissemination.

13 January 2022 in Cancer Letters
Verified
Journal Article
Closed access
DNDaichi Nomoto
Daichi Nomoto
YBYoshifumi Baba
Yoshifumi Baba
YLYang Liu
Yang Liu
HTHiroyasu Tsutsuki
Hiroyasu Tsutsuki
KOKazuo Okadome
Kazuo Okadome
HBHideo Baba
Hideo Baba

7 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KHKazuto Harada
Kazuto Harada
YBYoshifumi Baba
Yoshifumi Baba
HSHironobu Shigaki
Hironobu Shigaki
TITakatsugu Ishimoto
Takatsugu Ishimoto
KMKeisuke Miyake
Keisuke Miyake
HBHideo Baba
Hideo Baba
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been associated with patient prognosis. However, the significance of PIK3CA mutations in gastric cancer remains unclear. This retrospective study investigated the relationship between PIK3CA mutations and clinical outcomes in patients with gastric cancer. Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association between PIK3CA mutations and prognosis in human cancers. The study included 208 patients with gastric cancer who underwent surgical resection at Kumamoto University Hospital, Japan, between January 2001 and August 2010. Mutations in PIK3CA exons 9 and 20 were quantified by pyrosequencing assays. PIK3CA mutations were detected in 25 (12 %) of the 208 patients. Ten patients had c.1634A > G (p.E545G), 10 had c.1624G > A (p.E542K), 13 had c.1633G > A (p.E545K), nine had c.3139C > T (p.H1047R), and 1 had c.3140A > G (p.H1047Y) mutations. PIK3CA mutations were not significantly associated with any clinical, epidemiologic, or pathologic characteristic. Kaplan–Meier analysis showed no significant differences in disease-free survival (log rank P = 0.84) and overall survival (log rank P = 0.74) between patients with and without PIK3CA mutations. Mutations in PIK3CA did not correlate with prognosis in patients with gastric cancer, providing additional evidence for the lack of relationship between the two.

25 November 2023 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MLMeiyue Lou
Meiyue Lou
MIMasaaki Iwatsuki
Masaaki Iwatsuki
XWXiyu Wu
Xiyu Wu
WZWeiliyun Zhang
Weiliyun Zhang
CMChihiro Matsumoto
Chihiro Matsumoto
HBHideo Baba
Hideo Baba

27 September 2018 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
MIMasaaki Iwatsuki
Masaaki Iwatsuki
KHKazuto Harada
Kazuto Harada
SIShiro Iwagami
Shiro Iwagami
KEKojiro Eto
Kojiro Eto
TITakatsugu Ishimoto
Takatsugu Ishimoto
HBHideo Baba
Hideo Baba
Gastrointestinal stromal tumors (GIST) are rare and mesenchymal in origin with a yearly incidence of 10‐15 cases per million people. If it is technically resectable, surgical resection is the mainstay of therapy regardless of tumor location,. Although complete (R0) resection can be achieved in up to 85% of patients with primary disease, approximately 50% of patients experience recurrence or metastases within 5 years of primary resection. Moreover, prior to 2000, the prognosis of patients with advanced, inoperable GIST was poor because the molecular mechanism had not sufficiently been elucidated, thus effective therapy was lacking. The tyrosine kinase inhibitor imatinib, which selectively inhibits tyrosine kinase KIT, has shown substantial clinical benefit for patients with GIST. In clinical trials, imatinib treatment resulted in response rates of 40%‐55% and longer progression‐free survival for patients with a KIT‐positive unresectable or metastatic GIST. Furthermore, recent clinical trials have shown that giving imatinib after curative resection for high‐risk cases prolonged recurrence‐free survival and overall survival in an adjuvant setting. Several clinical trials of imatinib treatment in a neoadjuvant setting are ongoing; however, in clinical settings, there are problems to resolve, such as optimal agents, duration of administration, and postoperative management. In this review, we discuss the application of surgical options, combined with adjuvant/neoadjuvant or perioperative imatinib treatment and their potential impact on survival for patients with primary, recurrent, or metastatic GIST.